RELIEF THERAPEUTICS Holding SA announced independent institutional review board (IRB) approval for the protocol of an investigator-initiated trial to evaluate RLF-TD011 as an adjunctive treatment for patients diagnosed with cutaneous t-cell lymphoma (CTCL). The study will evaluate the effect of RLF-TD011, a patent-protected hypochlorous acid topical spray, on the microbiome of CTCL skin lesions and determine tolerability, symptom improvement, and potential for reducing lesion size and skin disease activity. The study will enroll participants at Northwestern department of dermatology in Chicago.

Microbiome assessments will be performed under the leadership of co-principal investigator Alan Zhou, M.D., MSc., fellow of the American Academy of Dermatology and assistant professor of dermatology at Northwestern University. CTCL is a rare, heterogeneous group of non-Hodgkin's lymphomas in which malignant t-cells infiltrate the skin. Advanced CTCL lesions harbor Staphylococcus aureus, which release toxins that stimulate malignant cells and drive disease progression.

This often leads to recurrent skin infections with a high risk for sepsis and death.